Target intelligence / Profile preview

Peptidoglycan precursor D-alanyl-D-alanine (D-Ala-D-Ala) terminus on lipid II (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Other, Bacterial cell wall precursor, Glycolipid
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the peptidoglycan precursor Lipid II is a fundamental structural component in the assembly of the bacterial cell wall, particularly in Gram-positive species (Nature Reviews Microbiology, 2008). Lipid II acts as a shuttle, transporting the building blocks of the peptidoglycan layer across the bacterial cell membrane. The terminal D-Ala-D-Ala dipeptide of the pentapeptide chain is the specific molecular target for glycopeptide antibiotics like vancomycin. When these drugs bind to the D-Ala-D-Ala motif, they create a steric block that prevents the enzymes transglycosylase and transpeptidase from incorporating the precursor into the growing peptidoglycan matrix (PubMed, PMID: 11586204). This inhibition halts cell wall synthesis, leading to bacterial lysis and death. Clinical resistance to these drugs often involves the enzymatic modification of the D-Ala-D-Ala terminus to D-Ala-D-Lac or D-Ala-D-Ser, which prevents antibiotic binding (StatPearls, 2023).

Other names
D-alanyl-D-alanineLipid II D-Ala-D-Ala terminusPeptidoglycan pentapeptide terminusD-Ala-D-Ala dipeptide
02

Mechanism of action

Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of the peptidoglycan precursor Lipid II via five hydrogen bonds, sterically inhibiting the transglycosylation and transpeptidation reactions required for cell wall synthesis (StatPearls, 2023).

03

Biological functions

OtherCell wall biosynthesisPeptidoglycan assemblyBacterial growth and division
04

Disease associations

Infection
05

Safety considerations

NephrotoxicityOtotoxicityInfusion-related reactions (Red man syndrome)Development of glycopeptide resistance (VRE, VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

Minimum Inhibitory Concentration (MIC)VanA geneVanB gene

Beyond the preview

Go deeper on Peptidoglycan precursor D-alanyl-D-alanine (D-Ala-D-Ala) terminus on lipid II (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan precursor D-alanyl-D-alanine (D-Ala-D-Ala) terminus on lipid II (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call